Evidence map›Paper›PMID 30041677›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma.

Yixue Gu, Hao Liu, Fangren Kong, Jiahui Ye, Xiaoting Jia, Zhijie Zhang, Nan Li, Jiang Yin, Guopei Zheng, Zhimin He

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. METTL3-mediated mThe Kaohsiung journal of medical sciences · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yixue GuAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Hao LiuAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Fangren KongAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Jiahui YeAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Xiaoting JiaAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Zhijie ZhangAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Nan LiAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Jiang YinAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China.
Guopei ZhengAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. zhengguopei@126.com.
Zhimin HeAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. hezhimin2005@yahoo.com.
Guangzhou Medical University · CN

Funding

National Natural Science Foundation of China No.81672616Natural Science Foundation of Guangdong Province No.2016A030306003Science and Technology Program of Guangzhou No. 201707010050Science and Technology Program of Guangzhou No.201710010100Scientific Research Project of Guangzhou Municipal Colleges and Universities No.1201610027Scientific Research Project of Guangzhou Municipal Colleges and Universities No. 1201630143
6 · The paper itself

Abstract

backgroundTongue squamous cell carcinoma (TSCC) is the most common oral cancer. Neoadjuvant systemic treatment before or after surgery for advanced TSCC is considered one of the most crucial factors in reducing mortality. However, the therapeutic benefits of chemotherapy are usually attenuated due to intrinsic and/or acquired drug resistance, and a large proportion of TSCC are resistant to chemotherapy, which may result in more aggressive tumor behavior and an even worse clinical outcome. Recently, the potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms remain to be understood in TSCC.

methodsThe expression of miR-22 in tissues from patients diagnosed with TSCC was analyzed using real-time PCR. The effects of miR-22 on cell proliferation and tumorigenesis in TSCC cells were analyzed by MTS assay, and flow cytometry. The tumor growth in vivo was observed in xenograft model. Luciferase reporter assay, real-time PCR and western blot were performed to validate a potential target of miR-22 in TC. The correlation between miR-22 expression and KAT6B expression, as well as the mechanisms by which miR-22 regulates PI3k-Akt-NF-kB pathway in TSCC were also addressed.

resultsWe found a strong correlation between miR-22 expression and chemosensitivity to cisplatin (CDDP) in TSCC patients. Ectopic overexpression of miR-22 enhanced TSCC cells apoptosis in response to CDDP in experimental models performed in vitro and in vivo. Moreover, we found that KAT6B is a direct functional target of miR-22. Ectopic expression of KAT6B attenuated the efficiency of miR-22 in TSCC cells upon CDDP treatment. Mechanistically, miR-22 overexpression or KAT6B knockdown inhibited PI3K/Akt/NF-κB signaling in TSCC cells, possibly via downregulating the activators of PI3K/Akt/NF-κB signaling, such as S100A8, PDGF and VEGF. Furthermore, the activation of miR-22 depended on the intensity of the stresses in the presence of p53 activation.

conclusionsOur findings define miR-22 as an intrinsic molecular switch that determines p53-dependent cellular fate through KAT6B/ PI3K-Akt/ NF-kB pathway.

Indexed as

Carcinoma, Squamous CellHumansMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTongue NeoplasmsTransfectionMicroRNAsMIRN22 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktChemotherapy responseKAT6BmiR-22NF-κBp53Tongue cancer

Identifiers

PMID30041677
PMCPMC6056941
OpenAlexW2884937981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.